<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Epigenomics</journal-id>
<journal-id journal-id-type="iso-abbrev">Epigenomics</journal-id>
<journal-id journal-id-type="publisher-id">EPI</journal-id>
<journal-title-group>
<journal-title>Epigenomics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1750-1911</issn>
<issn pub-type="epub">1750-192X</issn>
<publisher>
<publisher-name>Future Medicine Ltd</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26585570</article-id>
<article-id pub-id-type="pmc">4709177</article-id>
<article-id pub-id-type="doi">10.2217/epi.15.70</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epigenetic regulation of <italic>UBE3A</italic> and roles in human neurodevelopmental disorders</article-title>
<alt-title alt-title-type="running-head">LaSalle, Reiter &amp; Chamberlain</alt-title>
<alt-title alt-title-type="running-head">Epigenetic regulation of <italic>UBE3A</italic> &amp; roles in human neurodevelopmental disorders</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>LaSalle</surname>
<given-names>Janine M</given-names>
</name>
<xref ref-type="corresp" rid="C0001">*</xref>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reiter</surname>
<given-names>Lawrence T</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff2"></xref>
<xref ref-type="aff" rid="aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chamberlain</surname>
<given-names>Stormy J</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff4"></xref>
</contrib>
<aff id="aff1"><label>1</label>Medical Microbiology &amp; Immunology, Genome Center &amp; MIND Institute, University of California, Davis, CA 95616, USA</aff>
<aff id="aff2"><label>2</label>Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38163, USA</aff>
<aff id="aff3"><label>3</label>Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163, USA</aff>
<aff id="aff4"><label>4</label>Department of Genetics &amp; Developmental Biology &amp; Stem Cell Institute, University of Connecticut, Farmington, CT 06030, USA</aff>
</contrib-group>
<author-notes>
<corresp id="C0001">*Author for correspondence: <email xlink:href="mailto:jmlasalle@ucdavis.edu">jmlasalle@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement">
<p>
<bold>Financial &amp; competing interests disclosure</bold>
</p>
<p>The authors thank the NIH NINDS (R01NS076263) and the Prader–Willi Research Foundation for ongoing support of research in this area. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2015</year>
</pub-date>
<volume>7</volume>
<issue>7</issue>
<fpage>1213</fpage>
<lpage>1228</lpage>
<permissions>
<copyright-statement>© Future Medicine Ltd</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="epi-07-1213.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>The E3 ubiquitin ligase UBE3A, also known as E6-AP, has a multitude of ascribed functions and targets relevant to human health and disease. Epigenetic regulation of the <italic>UBE3A</italic> gene by parentally imprinted noncoding transcription within human chromosome 15q11.2–q13.3 is responsible for the maternal-specific effects of 15q11.2–q13.3 deletion or duplication disorders. Here, we review the evidence for diverse and emerging roles for UBE3A in the proteasome, synapse and nucleus in regulating protein stability and transcription as well as the current mechanistic understanding of <italic>UBE3A</italic> imprinting in neurons. Angelman and Dup15q syndromes as well as experimental models of these neurodevelopmental disorders are highlighted as improving understanding of UBE3A and its complex regulation for improving therapeutic strategies.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>Angelman syndrome</kwd>
<kwd>Dup15q syndrome</kwd>
<kwd>imprinting</kwd>
<kwd>neurodevelopment</kwd>
<kwd>proteosome</kwd>
<kwd>ubiquitin</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>